// App-Quantinova.ai

PB1733 : PHASE III MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RILZABRUTINIB, ORAL BTK INHIBITOR, IN ADULTS AND ADOLESCENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA

Researchers

Presenter

  • David J. Kuter

Principal Investigators

  • James B. Bussel

  • Nichola Cooper

  • Terry Gernsheimer

  • Michele P. Lambert

  • Howard A. Liebman

  • Michael D. Tarantino

  • Olga Bandman

  • Puneet Arora

  • Ann Neale

  • Regan Burns

  • Hailing Guo

  • Waleed Ghanima

Medical Centers

  • Østfold Hospital Foundation,Gralum,Noruega

  • University of Washington Medical Center Seattle WA United States

  • Hematology Division,Massachusetts General Hospital, Harvard Medical School,Boston,United States

  • Jane Anne Nohl Division of Hematology,Keck School of Medicine of University of Southern California,Los Angeles,United States

  • Division of Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, United States

  • Principia Biopharma Inc, a Sanofi Company,South San Francisco,United States

  • The Bleeding and Clotting Disorders Institute,Peoria IL,United States;University of Illinois College of Medicine-Peoria,Peoria IL,United States

  • Biostatistics, Sanofi US Services Inc.,Bridgewater,Estados Unidos

  • Division of Pediatric Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY

  • Department of Haematology,Guy's Hospital,London,United Kingdom

Locations

  • Norway

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Immune thrombocytopenia

Biomarkers

  • Bruton tyrosine kinase

Drug/Treatment

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT04562766

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved